Discover open access scientific publications

Search, annotate, share and cite publications

Publications by R. Huo

P3.13-21 Apatinib Plus Icotinib as First-Line Therapy for EGFR Co-Mutations NSCLC in Chinese Patients: An Exploratory Study

Journal of Thoracic Oncology

English

Related publications

P1.01-109 Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

P3.13-10 Factors Associated With Long-Term Survival of Stage IV NSCLC Patients on First-Line EGFR-Targeting Therapy

Journal of Thoracic Oncology

English

P3.13-24 Efficacy of EGFR-TKIs Compared With Chemotherapy as First-Line Therapy in Patients With EGFR Rare Mutation Advanced Lung Adenocarcinoma

Journal of Thoracic Oncology

English

Letter to the Editor Concerning First-Line Therapy With Afatinib – An Irreversible EGFR TKI and Overall Survival of NSCLC Patients With EGFR Gene Mutations

Wspolczesna Onkologia

English

P2.03-10 Gene Mutational Profiling of Chinese TKI-Sensitizing EGFR Mutations NSCLC Patients Required Resistance to Icotinib Using NGS

Journal of Thoracic Oncology

English

P1.13-26 First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant NSCLC Patients With Oligoprogressive Disease

Journal of Thoracic Oncology

English

P1.01-25 Carboplatin and Pemetrexed Plus Bevacizumab After Failure of First-Line EGFR-TKI Therapy for NSCLC Harboring EGFR Mutation (CJLSG 0908)

Journal of Thoracic Oncology

English

P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

Journal of Thoracic Oncology

English

Systemic Treatment in EGFR-ALK NSCLC Patients: Second Line Therapy and Beyond

Expert Review of Anticancer Therapy

Oncology

Pharmacology

2014

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by R. Huo

P3.13-21 Apatinib Plus Icotinib as First-Line Therapy for EGFR Co-Mutations NSCLC in Chinese Patients: An Exploratory Study

Related publications

P1.01-109 Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

P3.13-10 Factors Associated With Long-Term Survival of Stage IV NSCLC Patients on First-Line EGFR-Targeting Therapy

P3.13-24 Efficacy of EGFR-TKIs Compared With Chemotherapy as First-Line Therapy in Patients With EGFR Rare Mutation Advanced Lung Adenocarcinoma

Letter to the Editor Concerning First-Line Therapy With Afatinib – An Irreversible EGFR TKI and Overall Survival of NSCLC Patients With EGFR Gene Mutations

P2.03-10 Gene Mutational Profiling of Chinese TKI-Sensitizing EGFR Mutations NSCLC Patients Required Resistance to Icotinib Using NGS

P1.13-26 First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant NSCLC Patients With Oligoprogressive Disease

P1.01-25 Carboplatin and Pemetrexed Plus Bevacizumab After Failure of First-Line EGFR-TKI Therapy for NSCLC Harboring EGFR Mutation (CJLSG 0908)

P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

Systemic Treatment in EGFR-ALK NSCLC Patients: Second Line Therapy and Beyond